{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:31:48Z","timestamp":1781620308090,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T00:00:00Z","timestamp":1228867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T00:00:00Z","timestamp":1228867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Antibodies against cyclic citrullinated peptides (CCPs) are useful for diagnosing rheumatoid arthritis (RA). Antibodies to mutated citrullinated vimentin (MCV) were described recently in RA. The aims of this study were to evaluate the usefulness of anti-MCV for diagnosing RA in anti-CCP-negative patients and to monitor anti-MCV titres during infliximab therapy for RA.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We studied two groups of RA patients, one with (n = 80) and one without (n = 76) anti-CCP antibodies. The specificity of anti-MCV was evaluated by investigating 50 healthy controls and 158 patients with other rheumatic diseases (51 psoriatic rheumatism, 58 primary Sj\u00f6gren syndrome, and 49 ankylosis spondylitis). Serum anti-MCV and anti-CCP titres were measured in 23 patients after 6, 12, 18, and 24 months of infliximab treatment. Anti-CCP2 and anti-MCV levels were assayed using a commercial enzyme-linked immunosorbent assay. IgM rheumatoid factor was determined by nephelometry.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>In accordance with the cutoff values recommended by the manufacturer, the specificity of anti-MCV antibodies was 90.9%. We adjusted the cutoff values to obtain the same specificity as that of anti-CCP antibodies (94.2%). With this optimal cutoff, anti-MCV antibodies were found in 11.8% (9\/76) of RA patients without anti-CCP, and similarly, anti-CCP antibodies were found in 11.2% (9\/80) of RA patients without anti-MCV. Anti-MCV antibodies were positive in 6 patients who tested negative for both anti-CCP and rheumatoid factor. Anti-MCV titres were significantly decreased after 18 and 24 months of infliximab therapy compared with baseline (<jats:italic>P<\/jats:italic> &lt; 0.01) as a significant decrease of anti-CCP levels occurred only at 24 months (<jats:italic>P<\/jats:italic> &lt; 0.04). Moreover, an anti-MCV decrease was significantly associated with DAS28 (disease activity score using 28 joint counts) improvements 12 months into therapy.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Our results suggest that anti-MCV antibodies may be valuable for diagnosing RA in anti-CCP-negative patients without replacing them as an equivalent number of anti-CCP-positive RA patients test negative for anti-MCV. Moreover, anti-MCV antibodies could be useful for monitoring the effects of infliximab therapy.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar2570","type":"journal-article","created":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T19:12:45Z","timestamp":1228936365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy"],"prefix":"10.1186","volume":"10","author":[{"given":"Pascale","family":"Nicaise Roland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Grootenboer Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Hayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dieud\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chollet Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,10]]},"reference":[{"key":"2408_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","volume":"41","author":"RC Lawrence","year":"1998","unstructured":"Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Fleson DT, Giannini EH, Heyse SP, Hirsh R, Hochberg MC, Hunder GG, Liang MH, Pilemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998, 41: 778-799. 10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V.","journal-title":"Arthritis Rheum"},{"key":"2408_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002\/art.1780310302.","journal-title":"Arthritis Rheum"},{"key":"2408_CR3","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/archinte.1992.00400240041006","volume":"152","author":"RH Shmerling","year":"1992","unstructured":"Shmerling RH, Delbanco TL: How useful is the rheumatoid factor? An analysis of sensitivity, specificity and predictive value. Arch Intern Med. 1992, 152: 2417-2420. 10.1001\/archinte.152.12.2417.","journal-title":"Arch Intern Med"},{"key":"2408_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-642-76189-8_20","volume-title":"Rheumatoid Arthritis","author":"RM Hoet","year":"1992","unstructured":"Hoet RM, van Venrooij WJ: The antiperinuclear factor (APF) and antikeratin Abs (AKA) in rheumatoid arthritis. Rheumatoid Arthritis. Edited by: Smolen J, Kalden J. 1992, Berlin: Springer-Verlag, 299-318."},{"key":"2408_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens GA, Visser H, de Jong BA, Hoogen van den FH, Hazes JM, Breedveld FC, van Venrooij WJ: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000, 43: 155-163. 10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3.","journal-title":"Arthritis Rheum"},{"key":"2408_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/03009740410005403","volume":"33","author":"S Grootenboer-Mignot","year":"2004","unstructured":"Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, Meyer O, Chollet-Martin S, Labarre C: Second generation anti-cyclic citrullinated peptide (anti-CCP2) Abs can replace other anti-filaggrin Abs and improves RA diagnosis. Scand J Rheumatol. 2004, 33: 218-220. 10.1080\/03009740410005403.","journal-title":"Scand J Rheumatol"},{"key":"2408_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/ard.2003.008623","volume":"63","author":"S Dubucquoi","year":"2004","unstructured":"Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, Dutoit V, Fauchais AL, Hachulla E, Flipo RM, Prin L: Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis. 2004, 63: 415-419. 10.1136\/ard.2003.008623.","journal-title":"Ann Rheum Dis"},{"key":"2408_CR8","first-page":"2390","volume":"33","author":"T Matsui","year":"2006","unstructured":"Matsui T, Shimada K, Ozawa N, Hayakowa H, Hagiwara F, Nakyama H, Sugii S, Ozawa Y, Tohma S: Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol. 2006, 33: 2390-2397.","journal-title":"J Rheumatol"},{"key":"2408_CR9","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1136\/ard.2005.035691","volume":"64","author":"VPK Nell","year":"2005","unstructured":"Nell VPK, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, Smolen , Steiner G: Autoantibody profiling as early diagnostic prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 1731-1736. 10.1136\/ard.2005.035691.","journal-title":"Ann Rheum Dis"},{"key":"2408_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/03009740310004856","volume":"33","author":"MK Soderlin","year":"2004","unstructured":"Soderlin MK, Kastbom A, Kautiainen H, Leirisalo-Repo M, Strandberg G, Skogh T: Antibodies against citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol. 2004, 33: 185-188. 10.1080\/03009740310004856.","journal-title":"Scand J Rheumatol"},{"key":"2408_CR11","doi-asserted-by":"publisher","first-page":"R264","DOI":"10.1186\/ar1173","volume":"6","author":"F Bobbio-Pallavicini","year":"2004","unstructured":"Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther. 2004, 6: R264-272. 10.1186\/ar1173.","journal-title":"Arthritis Res Ther"},{"key":"2408_CR12","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard.2003.014647","volume":"63","author":"C Alessandri","year":"2004","unstructured":"Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G: Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF-alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis. 2004, 63: 1218-1221. 10.1136\/ard.2003.014647.","journal-title":"Ann Rheum Dis"},{"key":"2408_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/ard.2004.023523","volume":"64","author":"L De Rycke","year":"2005","unstructured":"De Rycke L, Verhelst X, Kruithof E, Bosch van der F, Hoffman IEA, Veys EM, De Keyser F: Rheumatoid factor but not anti-citrullinated peptide antibodies is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 299-302. 10.1136\/ard.2004.023523.","journal-title":"Ann Rheum Dis"},{"key":"2408_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.2003.012211","volume":"63","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar ER, Radstake TR, Heijden van der A, van Mansum MA, Dieteren C, de Rooij DJ, Barrera P, Zendman AJ, van Venrooij WJ: Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis. 2004, 63: 373-381. 10.1136\/ard.2003.012211.","journal-title":"Ann Rheum Dis"},{"key":"2408_CR15","first-page":"1027","volume":"21","author":"N Despres","year":"1994","unstructured":"Despres N, Boire G, Lopez-Longo FJ, Menard HA: The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol. 1994, 21: 1027-1033.","journal-title":"J Rheumatol"},{"key":"2408_CR16","first-page":"7","volume":"26","author":"G Hayem","year":"1999","unstructured":"Hayem G, Chazerain P, Combe B, Elias A, Haim T, Nicaise P, Benali K, Eliaou JF, Kahn MF, Sany J, Meyer O: Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol. 1999, 26: 7-13.","journal-title":"J Rheumatol"},{"key":"2408_CR17","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1186\/ar2008","volume":"8","author":"C Dejaco","year":"2006","unstructured":"Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M: Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther. 2006, 8: R119-10.1186\/ar2008.","journal-title":"Arthritis Res Ther"},{"key":"2408_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1373\/clinchem.2006.078063","volume":"53","author":"D Coenen","year":"2007","unstructured":"Coenen D, Verschueren P, Westhovens R, Bossuyt X: Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein\/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem. 2007, 53: 498-504. 10.1373\/clinchem.2006.078063.","journal-title":"Clin Chem"},{"key":"2408_CR19","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1373\/clinchem.2007.087569","volume":"53","author":"N Bizzaro","year":"2007","unstructured":"Bizzaro N, Tonutti E, Tozzoli R, Villalta D: Analytical and diagnostic characteristics of 11 2nd and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem. 2007, 53: 1527-1533. 10.1373\/clinchem.2007.087569.","journal-title":"Clin Chem"},{"key":"2408_CR20","first-page":"1658","volume":"34","author":"L Soos","year":"2007","unstructured":"Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF, Denko K, Kapitany A, Kegvari A, Sipka S, Szegedi G, Lakos G: Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol. 2007, 34: 1658-1663.","journal-title":"J Rheumatol"},{"key":"2408_CR21","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/art.22817","volume":"56","author":"H Bang","year":"2007","unstructured":"Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR: Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007, 56: 2503-2511. 10.1002\/art.22817.","journal-title":"Arthritis Rheum"},{"key":"2408_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/art.23188","volume":"58","author":"L Mathsson","year":"2008","unstructured":"Mathsson L, Mullazehi M, Wick MC, Sj\u00f6berg O, van Vollenhoven R, Llareskog L, R\u00f6nnelid J: Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008, 58: 36-45. 10.1002\/art.23188.","journal-title":"Arthritis Rheum"},{"key":"2408_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, Putte van de LB, van Riel PL: Modified disease activity scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 44-48. 10.1002\/art.1780380107.","journal-title":"Arthritis Rheum"},{"key":"2408_CR24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0002-9440(10)62045-7","volume":"167","author":"X Yang","year":"2005","unstructured":"Yang X, Wang J, Liu C, Grizzle WE, Yu S, Zhang S, barnes S, Koopman NJ, Mountz JD, Kimberly RP, Zhang HG: Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblasts. Am J Pathol. 2005, 167: 705-719.","journal-title":"Am J Pathol"},{"key":"2408_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00296-008-0614-8","volume":"29","author":"R Sghiri","year":"2008","unstructured":"Sghiri R, Bouajina E, Bargaoui D, Harzallah L, Fredj HB, Sammoud S, Ghedira I: Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int. 2008, 29: 59-62. 10.1007\/s00296-008-0614-8.","journal-title":"Rheumatol Int"},{"key":"2408_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/ard.2003.019794","volume":"64","author":"JE Gottenberg","year":"2005","unstructured":"Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, Labarre C, Meyer O, Sibilia J, Mariette X: Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sj\u00f6ogren's syndrome. Ann Rheum Dis. 2005, 64: 114-117. 10.1136\/ard.2003.019794.","journal-title":"Ann Rheum Dis"},{"key":"2408_CR27","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantap\u00e4\u00e4-Dahlqvist","year":"2003","unstructured":"Rantap\u00e4\u00e4-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against citrullinated peptides and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2741-2749. 10.1002\/art.11223.","journal-title":"Arthritis Rheum"},{"key":"2408_CR28","first-page":"1002","volume":"35","author":"L Innala","year":"2008","unstructured":"Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Rantap\u00e4\u00e4-Dahlqvist S: Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol. 2008, 35: 1002-1008.","journal-title":"J Rheumatol"},{"key":"2408_CR29","doi-asserted-by":"publisher","first-page":"R1200","DOI":"10.1186\/ar1812","volume":"7","author":"P Dieud\u00e9","year":"2005","unstructured":"Dieud\u00e9 P, Garnier S, Michou L, Petit-Texeira E, Glikmans E, Pierlot C, Lasbleiz S, Bardin T, Prum B, Cornelis F, European Consortium on Rheumatoid Arthritis Families: Rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22\u2013620 W allele. Arthritis Res Ther. 2005, 7: R1200-1207. 10.1186\/ar1812.","journal-title":"Arthritis Res Ther"},{"key":"2408_CR30","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar2214","volume":"9","author":"H Kokkonen","year":"2007","unstructured":"Kokkonen H, Johansson M, Innala L, Jidell E, Rantap\u00e4\u00e4-Dahlqvist S: The PTPN22 1858 C\/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther. 2007, 9: R56-10.1186\/ar2214.","journal-title":"Arthritis Res Ther"},{"key":"2408_CR31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.21739","volume":"54","author":"AH van der Helm-van Mil","year":"2006","unstructured":"Helm-van Mil van der AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR: The HLA-DRB1 shared epitope alleles are primarily a risk factor for anticyclic citrullinated peptide Abs and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006, 54: 1117-1121. 10.1002\/art.21739.","journal-title":"Arthritis Rheum"},{"key":"2408_CR32","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/ar1851","volume":"8","author":"F Atzeni","year":"2006","unstructured":"Atzeni F, Sarzi-Puttini P, Dell'Acqua D, de Portu S, Cecchini G, Cruini C, Carraba M, Meroni PL: Adalimumab clinical efficacy is associated with rheumatoid facto rand anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther. 2006, 8: R3-10.1186\/ar1851.","journal-title":"Arthritis Res Ther"},{"key":"2408_CR33","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1002\/art.20659","volume":"50","author":"TR Mikuls","year":"2004","unstructured":"Mikuls TR, O'Dell JR, Stoner JA, Parish LA, Arend WP, Norris JM, Holers VM: Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004, 50: 3776-3782. 10.1002\/art.20659.","journal-title":"Arthritis Rheum"},{"key":"2408_CR34","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar2362","volume":"10","author":"J Ursum","year":"2008","unstructured":"Ursum J, Nielen MM, van Schaardenburg D, Horst van der AR, Stadt van de RJ, Dijkmans BA, Hamann D: Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther. 2008, 10: R12-10.1186\/ar2362.","journal-title":"Arthritis Res Ther"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2570.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar2570\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2570.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:31:08Z","timestamp":1728383468000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar2570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,10]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,12]]}},"alternative-id":["2408"],"URL":"https:\/\/doi.org\/10.1186\/ar2570","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,10]]},"assertion":[{"value":"15 July 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R142"}}